Aravind Ramakrishnan, MD
Medical Oncology · Austin, TXNPI 1174686364
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 51.8% of the total. Reporting peaked in 2019 at $27,225 and has fallen 95.3% since, to $1,290 in 2025.
Across 181 payments — averaging $231.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$22K
- Amgen$12K
- Novartis$2K
- AstraZeneca$2K
- Johnson & Johnson$1K
- Astellas Pharma US Inc$670
- plus $3K from 21 others
Across 596 payments — averaging $5902.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$746K
- Pfizer$578K
- Janssen Research & Development, LLC$538K
- AstraZeneca$447K
- Sumitomo Pharma America, Inc.$399K
- Incyte Corporation$190K
- plus $621K from 10 others
What the payments were for
- Consulting fees$14,65535%
- Speaking & faculty fees$16,22539%
- Travel & lodging$4,46911%
- Food & beverage$6,59316%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $21,737 |
| Amgen | 11 | $11,608 |
| Novartis | 15 | $1,758 |
| AstraZeneca(2 entities) | 9 | $1,687 |
| Johnson & Johnson(2 entities) | 37 | $1,167 |
| Astellas Pharma US Inc | 22 | $670 |
| Sanofi-aventis U.S. LLC | 6 | $428 |
| Kadmon Pharmaceuticals LLC | 1 | $390 |
| Daiichi Sankyo Inc. | 10 | $378 |
| Gilead(2 entities) | 4 | $313 |
| Janssen Scientific Affairs, LLC | 5 | $308 |
| Legend Biotech USA Inc. | 10 | $297 |
| Jazz Pharmaceuticals Inc. | 3 | $165 |
| GSK | 5 | $161 |
| Janssen Research & Development, LLC | 1 | $146 |
| Bristol Myers Squibb | 5 | $128 |
| Incyte Corporation | 1 | $125 |
| Genentech, Inc. | 1 | $122 |
| AbbVie | 1 | $122 |
| Seagen Inc. | 1 | $96 |
| Genentech USA, Inc. | 2 | $37 |
| Beigene USA, Inc. | 2 | $37 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Beone Medicines USA, Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,985 in reported general payments places this provider in the 75th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 107 | $3,782 |
| Ursodiol | 11 | $2,199 |
| Morphine Sulfate ErMorphine Sulfate | 33 | $1,288 |
| Fluconazole | 16 | $522 |
| Acyclovir | 31 | $488 |
| Duloxetine Hcl | 36 | $396 |
| Oxycodone Hcl | 22 | $235 |
| Rosuvastatin Calcium | 20 | $218 |
| Famotidine | 11 | $183 |
| Pantoprazole Sodium | 23 | $180 |
| Gabapentin | 25 | $171 |
| Allopurinol | 27 | $150 |
| Atorvastatin Calcium | 24 | $138 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 34 | $115 |
| Prednisone | 22 | $106 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Austin
- Sue EckhardtAustin$1.5M
- Miguel AlbinoAustin$322K
- Jason MelearAustin$229K
- Andrew BrennerAustin$125K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.